Kimberly-Clark Corp. (NYSE:KMB) is reportedly preparing concessions to address European Union antitrust concerns over its proposed $40 billion acquisition of Tylenol maker Kenvue Inc. (NYSE:KVUE).
European Regulatory Scrutiny
The European Commission is expected to formally outline its competition concerns to Kimberly-Clark this week, Reuters reported, citing people familiar with the matter.
Kimberly-Clark could offer concessions before the EU’s preliminary review ends Sept. 29. Otherwise, regulators could open an in-depth investigation lasting about four months.
The potential remedies could include asset sales aimed at easing competition concerns and securing EU approval for the $40 billion transaction.
The deal, announced in November 2025, would bring Kenvue brands such as Neutrogena, Aveeno and Listerine into Kimberly-Clark’s portfolio, which includes Kleenex and Huggies.
Australia Required Asset Sales
Australia has already imposed conditions on the transaction.
Earlier this month, the Australian Competition and Consumer Commission approved the acquisition on the condition that Kenvue’s Stayfree and Carefree period-care brands are sold to an approved buyer.
Before the proposed deal, Kimberly-Clark and Kenvue were two of Australia’s three major period-care suppliers. Essity, which owns the Libra and TOM Organic brands, was the third.
The regulator said the divestiture would preserve competition that could otherwise be lost through the combination.
Stock Performance And Technical Analysis
Kimberly-Clark stock is trading higher Wednesday morning as broader market sentiment improves. Nasdaq futures are up 0.54%, while S&P 500 futures have gained 0.32%.
The stock is attempting to stabilize after a prolonged decline. Kimberly-Clark has fallen 21.09% over the past 12 months.
Kimberly-Clark remains in a longer-term downtrend. At $99, the stock is trading below all four major moving averages.
It sits 6.7% below its 20-day SMA of $106.06 and 8.6% below its 50-day SMA of $108.28. It is also 5.2% below the 100-day SMA of $104.43 and 4% below the 200-day SMA of $103.09.
However, momentum looks stretched. The relative strength index stands at 30, putting the stock near oversold territory. That could support a short-term rebound, although it does not signal a trend reversal on its own.
The 20-day SMA remains below the 50-day SMA, signaling short-term weakness. However, the 50-day SMA is still above the 200-day SMA following a golden cross in July.
Resistance sits near $111.50. Support is around $93, close to the 52-week low of $92.42.
Kimberly-Clark Analyst Outlook
The stock carries a Hold consensus rating with an average price forecast of $112.43.
Piper Sandler maintained an Overweight rating and lowered its price forecast to $118 on Sept. 11. Wells Fargo maintained Equal-Weight and cut its forecast to $105 on Sept. 10. UBS maintained Neutral and raised its forecast to $116 on Aug. 5.
Benzinga Edge Rankings
The Benzinga Edge scorecard highlights a sharp divide between Kimberly-Clark’s fundamentals and stock performance.
Kimberly-Clark scores 98.09 for Quality and 84.27 for Growth. However, its Momentum score is just 18.66, reflecting the stock’s prolonged weakness. Its Value score stands at 33.05.
Kimberly-Clark ETF Exposure
Kimberly-Clark is held by the Invesco NASDAQ Next Gen 100 ETF (NASDAQ:QQQJ), Franklin U.S. Low Volatility High Dividend Index ETF (NASDAQ:LVHD) and Invesco S&P 500 Equal Weight Consumer Staples ETF (NYSE:RSPS).
Price Action: Kimberly-Clark shares were up 0.33% at $99.00 and Kenvue shares were up 0.28% at $17.97 during premarket trading on Wednesday, according to Benzinga Pro data.
Photo via Shutterstock
Login to comment